MeSH tree: C10.114
Myasthenia gravis (MG) is a rare, chronic autoimmune disorder that disrupts the communication between nerves and muscles. It typically leads to symptoms such as muscle weakness, drooping eyelids, difficulty swallowing, fatigue, ...
May 13, 2025
0
28
For female patients with multiple sclerosis (MS), transcutaneous posterior tibial nerve stimulation (TPTNS) and repetitive transcranial magnetic stimulation (rTMS) are comparable for neurogenic overactive bladder symptoms, ...
May 7, 2025
0
12
More than 280,000 people in Germany have multiple sclerosis (MS) and approximately 15,000 new cases are diagnosed each year. This makes MS the most common inflammatory disease of the central nervous system.
May 7, 2025
0
78
Researchers at the University of Turku, Finland, have discovered a new biomarker that can predict the progression of multiple sclerosis (MS).
Apr 29, 2025
0
233
To provide the right treatment for multiple sclerosis (MS), it is important to know when the disease changes from relapsing-remitting to secondary progressive, a transition that is currently recognized on average three years ...
Apr 28, 2025
0
68
Imagine suddenly losing the ability to move a limb, walk or speak. You would probably recognize this as a medical emergency and get to hospital.
Apr 24, 2025
0
28
Research published in the Journal of Neurochemistry has detailed the role of a protein, hnRNP A1, in the formation and stability of myelin, suggesting an important impact on neurodegenerative diseases and mental disorders ...
Apr 17, 2025
0
21
The U.S. Food and Drug Administration has approved a self-injection version of Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult patients with generalized myasthenia gravis (gMG) who are ...
Apr 16, 2025
0
28
A University of Alberta study shows that rural Albertans living with multiple sclerosis are not as likely as urban patients to receive the best treatments to prevent relapses and slow down progression of the disease.
Apr 15, 2025
0
11
New research led by a St. Michael's Hospital clinician-scientist and published in the New England Journal of Medicine suggests that a therapy called Tolebrutinib could reduce disability progression in people with non-relapsing ...
Apr 9, 2025
0
25
